Retatrutide: The Triple Agonist Explained

Retatrutide (LY3437943) is an investigational peptide developed by Eli Lilly that activates three receptor systems simultaneously: GLP-1, GIP, and glucagon receptors. This makes it a "triple agonist" — the first of its kind to reach late-stage clinical trials. While Semaglutide targets one receptor (GLP-1) and Tirzepatide targets two (GLP-1 + GIP), Retatrutide adds glucagon receptor activation, potentially unlocking additional metabolic benefits.

The addition of glucagon receptor agonism is what makes Retatrutide unique. Glucagon is traditionally thought of as a blood sugar-raising hormone, the opposite of insulin. However, glucagon also has powerful effects on energy expenditure and fat metabolism:

Glucagon increases hepatic fat oxidation, meaning the liver burns more stored fat for energy. It raises resting metabolic rate, so the body burns more calories even at rest. It also promotes thermogenesis — the production of heat from stored energy. These effects complement the appetite suppression provided by GLP-1 and the insulin sensitization from GIP, creating a three-pronged approach to weight loss that no other medication currently offers.

In the Phase 2 trial published in the New England Journal of Medicine (2023), Retatrutide produced the most dramatic weight loss results ever seen in a pharmaceutical trial:

At the highest dose (12 mg weekly), participants lost an average of 24.2% of their body weight over 48 weeks. Some participants lost over 30%. By comparison, Semaglutide produces roughly 15-17% weight loss and Tirzepatide 20-22% over similar timeframes.

Retatrutide also showed remarkable effects on liver fat. In a sub-study, 86% of participants with non-alcoholic fatty liver disease (NAFLD) achieved complete resolution of liver fat — a result that has generated significant interest from hepatologists. Phase 3 trials are underway with results expected in 2026-2027.

Retatrutide is administered as a once-weekly subcutaneous injection, similar to Semaglutide and Tirzepatide. The Phase 2 trial tested doses of 1, 4, 8, and 12 mg weekly, with dose escalation over the first few months to manage gastrointestinal side effects.

The dose escalation typically starts at 2 mg weekly for the first month, increases to 4 mg, then 8 mg, and finally 12 mg over several months. This gradual approach is critical — jumping to higher doses without escalation dramatically increases nausea and other GI symptoms.

The side effect profile is similar to other GLP-1 agonists but with some notable differences. Gastrointestinal effects dominate: nausea (affected roughly 25-45% depending on dose), diarrhea, vomiting, and constipation. These are typically worst during dose escalation and improve over time.

The glucagon component raises a theoretical concern about blood sugar elevation, but clinical data has not shown this to be a problem — the GLP-1 and GIP components appear to counterbalance any hyperglycemic effect from glucagon activation.

Heart rate increases of 2-4 bpm were observed, consistent with GLP-1 agonists. Retatrutide carries the same class-wide thyroid C-cell tumor boxed warning as Semaglutide and Tirzepatide.

Retatrutide vs Semaglutide: Roughly 7-9% more body weight lost. Triple mechanism vs single mechanism. Retatrutide is investigational; Semaglutide is FDA-approved and widely available.

Retatrutide vs Tirzepatide: Roughly 3-5% more body weight lost. The glucagon component adds metabolic benefits (increased energy expenditure, liver fat reduction) that Tirzepatide does not provide. Both are Eli Lilly products.

Retatrutide is not yet approved or available by prescription. It is currently in Phase 3 clinical trials. If approved, it would represent the most effective pharmaceutical weight loss treatment available.